Cantor Fitzgerald Weighs in on Verastem FY2025 Earnings

Verastem, Inc. (NASDAQ:VSTM) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Verastem in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the biopharmaceutical company will post earnings per share of ($3.24) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share.

Verastem (NASDAQ:VSTM) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.11.

A number of other equities analysts also recently issued reports on VSTM. Royal Bank of Canada increased their target price on Verastem from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Verastem in a research report on Thursday, December 19th. Mizuho boosted their target price on shares of Verastem from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, December 19th. BTIG Research increased their price target on shares of Verastem from $13.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Finally, StockNews.com cut shares of Verastem from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Verastem presently has an average rating of “Moderate Buy” and an average target price of $13.38.

Verastem Trading Up 1.3 %

NASDAQ VSTM opened at $5.59 on Thursday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 2.77. The stock has a market capitalization of $248.81 million, a P/E ratio of -1.75 and a beta of 0.24. Verastem has a 52-week low of $2.10 and a 52-week high of $14.22. The firm has a 50-day moving average price of $4.91 and a 200 day moving average price of $3.63.

Institutional Trading of Verastem

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC purchased a new position in Verastem in the 3rd quarter valued at about $41,000. SG Americas Securities LLC purchased a new position in shares of Verastem during the third quarter valued at approximately $43,000. JPMorgan Chase & Co. boosted its position in Verastem by 55.4% during the third quarter. JPMorgan Chase & Co. now owns 16,878 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 6,016 shares during the last quarter. Apollon Wealth Management LLC grew its stake in Verastem by 104.6% in the 3rd quarter. Apollon Wealth Management LLC now owns 20,457 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 10,457 shares during the period. Finally, Rhumbline Advisers raised its holdings in Verastem by 4,172.0% in the 2nd quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 28,119 shares during the last quarter. Hedge funds and other institutional investors own 88.37% of the company’s stock.

Insider Activity at Verastem

In other news, CEO Dan Paterson sold 8,568 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $5.24, for a total value of $44,896.32. Following the completion of the transaction, the chief executive officer now directly owns 347,581 shares of the company’s stock, valued at $1,821,324.44. The trade was a 2.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders have sold 10,321 shares of company stock valued at $52,217. Insiders own 2.20% of the company’s stock.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.